29102-72-5

Usage

Uses

Used in Organic Synthesis:
1-(3-bromopropoxy)-2,4,5-trichlorobenzene is used as an intermediate in organic synthesis for its unique molecular structure that can be further modified or reacted to produce a range of other compounds. Its presence of chlorine, bromine, and oxygen atoms allows for versatile chemical reactions, making it a valuable building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Chemical Reactions:
In the chemical industry, 1-(3-bromopropoxy)-2,4,5-trichlorobenzene is used as a reactant in various chemical reactions due to its reactive functional groups. The chlorine and bromine atoms can be replaced by other functional groups through substitution reactions, while the propoxy group can participate in etherification or esterification reactions, leading to the formation of new compounds with different properties and applications.
Used in Material Science:
1-(3-bromopropoxy)-2,4,5-trichlorobenzene is also utilized in material science as a component in the development of novel materials with specific properties. Its unique structure can contribute to the formation of polymers with tailored characteristics, such as improved thermal stability, chemical resistance, or mechanical strength. Additionally, it may be used in the creation of advanced coatings, adhesives, or elastomers that require specific chemical and physical properties.

Upstream product

• 95-95-4 2,4,5-trichlorophenol 
• 109-64-8 1,3-dibromo-propane 

Downstream Products

• 99360-86-8 4-(2,4,5-trichloro-phenoxy)-butyronitrile 
• 103796-47-0 5-(2,4,5-trichloro-phenoxy)-valeric acid 
• 6954-82-1 [3-(2,4,5-trichloro-phenoxy)-propyl]-phosphonic acid diethyl ester 
• 29102-73-6 3-(2,4,5-Trichlorphenoxy)-propyl-benzhydroxamat 
• 1419608-35-7 P₆₅ 
• 152662-90-3 PS-15 

Relevant academic research and scientific papers

Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors

A novel series of dihydro-1,3,5-triazine derivatives bearing a heteroatom spiro-ring were designed and synthesized on the basis of molecular flexible docking work, and their biological activities were evaluated. Compounds A2, A5, B1 and B3 showed potent human dihydrofolate reductase (hDHFR) inhibitory activity with IC50values of 7.46 nM, 3.72 nM, 6.46 nM, 4.08 nM, versus reference drug methotrexate (MTX). From the molecular docking result we concluded that the conformation space generated by deformation of the flexible residue Phe31 is favorable for the binding of the spiro-ring, and inserting heteroatom into spiro ring might increase the binding affinity. There were 24 compounds with broadspectrum antiproliferative activity against several tumor cell lines (HCT116, A549, HL-60, HepG2 and MDA-MB-231) with IC50values ranging from 0.79 to 0.001 μM. The antitumor activity in?vivo of compound A2 was determined in a human alveolar basal epithelial cell line A549 xenograft model. This study offered novel anticancer agents with high inhibitory activity that target hDHFR and have a binding mode of the novel molecular scaffold with hDHFR. This provides potent support for further development of novel hDHFR inhibitors.

Diamino triazines derivatives, their salts, preparation method, composition and use thereof

The invention discloses derivatives and salts of damino dihydrotriazine, and a preparation method, a composition and application thereof. According to the invention, the preparation method of the damino dihydrotriazine derivative and the damino dihydrotriazine salt can be realized by adopting a method I or a method II, wherein the method I includes the step of obtaining a general formula I compound prepared through the reaction between a general formula IV compound and a general formula V compound, while the method II includes the step of mixing a general formula VIII compound with a general formula II compound under an acidic condition, and obtaining the compound shown in the general formula I through a cyclization reaction of the mixture. The invention also provides application of derivatives and salts of the damino dihydrotriazine in preparation of human dihydrofolate reductase inhibitors, preventing and curing drugs for tumor or bacterial infection diseases. The invention further provides a drug composition, which comprises an effective amount of the derivatives and/or salts of the damino dihydrotriazine, as well as pharmaceutically acceptable carriers. According to the invention, spiro heterocyclic ring derivatives of the damino dihydrotriazine have an excellent inhibitory activity on human dihydrofolate reductase, tumor cells and bacteria.

Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials

A total of 34 analogues of the biguanide PS-15 (5s), a prodrug of the diaminotriazine WR-99210 (8s), have been prepared. Several of them, such as 5b (PS-33) and 5m (PS-26), maintain or exceed the in vivo activity of PS-15 while not requiring the use of highly regulated starting materials. The putative diaminotriazine metabolites of these new analogues (compounds 8) have also been prepared and shown to maintain the activity against resistant P. falciparum strains. The structure-activity relationships of biguanides 5 and putative metabolites 8 are discussed.

N,N'-substituted imidodicarbonimidic diamides derived from hydroxylamines

There are provided compounds of the formula STR1 wherein R1 is a substituted or unsubstituted divalent aliphatic group of 1 to 16 carbon atoms; wherein the substituents are mono or poly and are selected from the group consisting of lower alkyl,